ReviewCell transplantation
Cell therapy for type 1 diabetes: Tracing historical progress and exploring emerging technologies.
Review in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Stem cell strategies for cell replacement therapy in endocrine diseases.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes remains an incurable autoimmune disease, and despite advances in insulin-delivery systems, many patients still face severe hypoglycemia, glucose variability, and psychological burden. Beta-cell replacement offers a transformative alternative, with allogeneic islet transplantation providing durable protection and improved quality of life, yet limited by donor availability and the need for immunosuppression. Stem cell-derived islet-like clusters are now reaching clinical milestones, showing promising insulin independence and glycemic control, while encapsulation, autologous induced pluripotent stem cells (iPSC)-derived therapies, and gene-edited "hypo-immune" cells aim to overcome immune barriers. Porcine islet xenotransplantation is also being revisited, although regulatory and immunological hurdles remain. Key challenges persist in cell delivery, engraftment, and long-term function. As cell therapy transitions from experimental proof-of-concept to clinical reality, success will require scalable manufacturing, safe and effective delivery, regulatory alignment, and patient-centered approaches to ensure broad and meaningful impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.